Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Study of electroreflectance spectrum and Franz-Keldysh effect at metal-GaAs interfaces].

Guang pu xue yu guang pu fen xi = Guang pu·2008

Same author

[Study on electro-degradation of new conjugated polymer PFO-BT15 light emitting diodes].

Guang pu xue yu guang pu fen xi = Guang pu·2008

Same author

Comparison of the curative effects of video assisted thoracoscopic anterior correction and small incision, thoracotomic anterior correction for idiopathic thoracic scoliosis.

Chinese medical journal·2008

Same author

Distribution and sources of mercury in soils from former industrialized urban areas of Beijing, China.

Environmental monitoring and assessment·2008

Same author

[Main flavonoids from Sophora flavescenes].

Yao xue xue bao = Acta pharmaceutica Sinica·2008

Same author

External validation and prediction employing the predictive squared correlation coefficient test set activity mean vs training set activity mean.

Journal of chemical information and modeling·2008

Same journal

Development and Validation of a Pathomics Model for Prognosis Prediction in Neoadjuvant Therapy-Treated Breast Cancer: A Retrospective, Multicenter Study.

MedComm·2026

Same journal

Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.

MedComm·2026

Same journal

Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies.

MedComm·2026

Same journal

Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management.

MedComm·2026

Same journal

Metabolic Dysfunction-Associated Fatty Liver Disease: From Pathogenesis to Treatment.

MedComm·2026

Same journal

Dexmedetomidine Rapidly Relieves Stress-Induced Hyperalgesia via Presynaptic <i>α</i>2-Adrenergic Inhibition at Orbitofrontal-Insular Glutamatergic Synapses.

MedComm·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Melanoma: Pathogenesis and Targeted Therapy.

Yang Fu¹, Jie Liu¹, Zeming Mo¹

¹Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu China.

|January 6, 2026

Summary

This summary is machine-generated.

Targeted therapies and immunotherapies have transformed melanoma treatment. MEK inhibitors show promise for NRAS-mutant melanoma, addressing a previously untreatable target.

Keywords:

BRAF NRAS immunotherapy melanoma targeted therapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Experiment Videos

Last Updated: Jan 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Area of Science:

Oncology
Dermatology
Molecular Biology

Background:

Melanoma is an aggressive skin cancer with common mutations in NRAS, BRAF, or NF1.
Targeted therapies offer significant antitumor activity for driver alterations.
BRAF and MEK inhibitor combinations have improved outcomes for BRAF-mutant melanoma.

Purpose of the Study:

To review the molecular pathogenesis and classification of melanoma.
To explore current and potential treatment strategies for melanoma.
To focus on the clinical development of BRAF inhibitors, MEK inhibitors, and immunotherapy.

Main Methods:

Literature review of molecular pathogenesis and classification.
Analysis of current and emerging treatment approaches.
Focus on clinical relevance and development of targeted therapies and immunotherapy.

Main Results:

BRAF/MEK inhibitors significantly improved BRAF-mutant melanoma prognosis.
MEK inhibitors demonstrate efficacy in NRAS-mutant melanoma, with tunlametinib approval.
Immune checkpoint inhibitors have reshaped advanced melanoma treatment.

Conclusions:

Melanoma treatment has advanced with targeted therapies and immunotherapy.
NRAS-mutant melanoma is becoming targetable with MEK inhibitors.
Challenges remain in optimizing immunotherapy and targeted therapy for melanoma.